Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- 03/28/11 -- SCYNEXIS, Inc. announced today that Dr. Dennis Schmatz has joined the company as a strategic advisor. Dr. Schmatz, an industry leader in the field of anti-infectives, will provide counsel to SCYNEXIS' management team as the Company advances its drug development programs.
"Dr. Schmatz brings outstanding capabilities and an extensive background, especially in the area of anti-infectives, and has played a key role in the discovery and development of a number of currently marketed therapeutic agents," said Dr. Yves Ribeill, SCYNEXIS President and Chief Executive Officer. "His contributions to SCYNEXIS will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases."
Dr. Schmatz most recently was the Interim President and Chief Executive Officer of Medicines for Malaria Venture, a nonprofit foundation in Geneva, Switzerland created to discover, develop and deliver new, affordable anti-malarial drugs through effective public-private partnerships. Previously he was the vice president of Merck Research Laboratories USA and the Head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.
"It's an exciting time to be joining the SCYNEXIS team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development," Schmatz said. "I see a promising future for SCYNEXIS and am honored to be a part of it."
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. Our record of success is demonstrated by the delivery of 11 pre-clinical and clinical drug candidates over the last 5 years. Located in Research Triangle Park, North Carolina, SCYNEXIS is developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.
For further information, please contact: SCYNEXIS, Inc. Terry Marquardt Executive Director Market Development & Communications terry.marquardt@scynexis.com Tel: +1-919-544-8603 SCYNEXIS Media Contacts: Rick Rountree Rick Rountree Communications, Inc. rick@rickrountree.com Tel. +1 919-878-1144 Sarah Cavanaugh MacDougall Biomedical Communications scavanaugh@macbiocom.com Tel. +1 781-235-3060
Source: SCYNEXIS, Inc.
Released March 28, 2011